You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductClenbuterol (Cat. No. 0688) has been withdrawn from sale for commercial reasons.
β 2 agonist (Ki values are 60, 190 and 1100 nM for β 2, β 1 and β 3 receptors respectively). Bronchodilator, tocolytic.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Marin and Balfagon (1998) Effect of clenbu. on non-endothelial nitric oxide release in rat mesenteric arteries and the involvement of β-adrenoceptors. Br.J.Pharmacol. 124 473 PMID: 9647470
Strosberg and Pietri-Rouxel (1996) Function and regulation of the β3 adrenoceptor. TiPS 17 373 PMID: 8979772
Merck Index 12 2407
View Related Products by Product Action
Keywords: Clenbuterol, Clenbuterol supplier, Adrenergic, Beta-2, Receptors, 0688, Tocris Bioscience
Citations for Clenbuterol
Citations are publications that use Tocris products.
Currently there are no citations for Clenbuterol.
Reviews for Clenbuterol
There are currently no reviews for this product. Be the first to review Clenbuterol and earn rewards!
Have you used Clenbuterol?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.